Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma

Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches

(2019) Wenbo Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma

(2019) Arghya Ray et al.   LEUKEMIA

Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges

(2019) Ilenia Pacella et al.   Frontiers in Immunology

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

(2018) Jooeun Bae et al.   LEUKEMIA

Promise of Immune Therapies in Multiple Myeloma

(2018) Kenneth C. Anderson   Journal of Oncology Practice

E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs

(2018) Enguang Bi et al.   JOURNAL OF CLINICAL INVESTIGATION

Alpha-Enolase i ENO1 i a potential target in novel immunotherapies

(2017) Francesco Novelli   Frontiers in Bioscience-Landmark

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

(2017) A Ray et al.   LEUKEMIA

Therapeutic Advances in Relapsed or Refractory Multiple Myeloma

(2017) Kenneth C. Anderson   Journal of the National Comprehensive Cancer Network

The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia

(2016) M Qorraj et al.   LEUKEMIA

Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma

(2015) P. Maiso et al.   CANCER RESEARCH

ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas

(2015) Xinghua Zhu et al.   EXPERIMENTAL CELL RESEARCH

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

(2015) A Ray et al.   LEUKEMIA

An update on therapeutic opportunities offered by cancer glycolytic metabolism

(2014) Carlotta Granchi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Preparation and characterization of vorinostat-coated beads for profiling of novel target proteins

(2014) Congcong Lu et al.   JOURNAL OF CHROMATOGRAPHY A

A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib

(2014) A Ray et al.   LEUKEMIA

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

(2014) C J Heuck et al.   LEUKEMIA

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid

(2014) Oscar R. Colegio et al.   NATURE

A Unique Small Molecule Inhibitor of Enolase Clarifies Its Role in Fundamental Biological Processes

(2013) Da-Woon Jung et al.   ACS Chemical Biology

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

(2013) H. A. F. Stessman et al.   MOLECULAR CANCER THERAPEUTICS

The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma

(2012) Kenneth C. Anderson   JOURNAL OF CLINICAL ONCOLOGY

Passenger deletions generate therapeutic vulnerabilities in cancer

(2012) Florian L. Muller et al.   NATURE

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL